Nebulized Ensifentrine

Phase 2

VERONA PHARMA (VRNA)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

VRNAPhase 2$1.1B

Nebulized Ensifentrine Phase 2 Est. Readout

Nebulized Ensifentrine• Non-cystic Fibrosis Bronchiectasis284

Q3 2027~QEstimated

CT.gov

00%

Competitive Landscape

3 competitors in Non-cystic Fibrosis Bronchiectasis

INSMBrensocatib 25 mg

Phase 3

ARMPAP-PA02

Phase 2

INSMBrensocatib 10 mg

Phase 2

View Full Landscape

Drug Information

Target Indication

Non-cystic Fibrosis Bronchiectasis

Clinical Trial

NCT06559150

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VRNA

VERONA PHARMA

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

EnsifentrinePhase 3

Chronic Obstructive Pulmonary Disease

Tiotropium/olodaterol (Respimat)Phase 2

COPD

RPL554 suspensionPhase 2

COPD

RPL554Phase 2

Cystic Fibrosis

Ensifentrine Dose 1Phase 2

Coronavirus Infection

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts